All In Biotech

Drug Trial Radar · NCT07397611

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOSHIFT-RCC)

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Mar 9, 2026

Primary completion

Jan 31, 2028

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arcus Biosciences, Inc.
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)

Conditions

  • Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Neoplasm
  • Renal Carcinoma

Interventions

  • CasdatifanDrug

    HIF-2α inhibitor, tablet taken orally per protocol.

  • ZimberelimabDrug

    monoclonal antibody, multi-dose vial, via intravenous (through the vein) infusion, per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor Size Reduction RateTime frame: Disease assessment will occur at pre-surgery visit week 11 ± 2 weeks.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.